Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
No effective interventions to reduce risk for new-onset diabetes after transplantation (NODAT), a condition associated with postoperative hyperglycemia and reduced patient and graft survival, have been established. In this 1-year, proof-of-concept clinical trial, we randomly assigned 50 renal transplant recipients to immediate-postoperative isophane insulin for evening blood glucose ≥140 mg/dl (treatment group) or short-acting insulin and/or oral antidiabetic agents for blood glucose ≥180-250 mg/dl (standard-of-care control group). We included only patients without a history of diabetes who received tacrolimus. By the third postoperative evening, all patients in the treatment group had blood glucose ≥140 mg/dl and were subsequently treated with basal insulin; during the first 3 weeks after transplantation, the mean ± SD daily insulin dosage was 17±11 IU/d. Among controls, 23 (92%) of 25 had blood glucose ≥200 mg/dl and 18 (72%) of 25 received standard-of-care antihyperglycemic treatment. Asymptomatic hypoglycemia occurred five times in the treatment group and once in the control group. Throughout follow-up, the treatment group had 73% lower odds of NODAT (odds ratio, 0.27) than the control group, and hemoglobin A1c was on average 0.38% lower in the treatment group than the control group. Twelve months after transplantation, all patients in the treatment group were insulin-independent, whereas 7 (28%) of 25 controls required antidiabetic agents. The groups did not differ for insulin sensitivity, but the treatment group showed better β-cell function throughout the 1-year follow-up. In conclusion, this study suggests regimens that include basal insulin significantly reduce the odds for NODAT after renal transplantation, presumably via insulin-mediated protection of β cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119
Intensive insulin therapy and pentastarch resuscitation in severe sepsis
Brunkhorst, F. M., Engel, C., Bloos, F., Meier-Hellmann, A., Ragaller, M., Weiler, N., Moerer, O., Gruendling, M., Oppert, M., Grond, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070716 · Cited by 2,921
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780
Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin
Bry, L., Chen, P. C., & Sacks, D. B. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.2.153 · Cited by 523
Ilkova, H., Glaser, B., Tunçkale, A., Bagriaçik, N., & Cerasi, E. (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1353 · Cited by 269
Cited by
Chadban, S. J., Ahn, C., Axelrod, D. A., Foster, B. J., Kasiske, B. L., Kher, V., Kumar, D., Oberbauer, R., Pascual, J., Pilmore, H. L., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003136 · Cited by 738
Sharif, A., Hecking, M., de Vries, A. P. J., Porrini, E., Hornum, M., Rasoul-Rockenschaub, S., Berlakovich, G., Krebs, M., Kautzky-Willer, A., Schernthaner, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12850 · Cited by 532
“In a randomized controlled trial, Hecking et al (12) demonstrated the benefit of early basal insulin therapy following detection of early posttransplant hyperglycemia (<3 weeks) at reducing subsequent odds of developing PTDM within the first year posttransplantation by 73%.”
BackgroundPost-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
Neuberger, J. M., Bechstein, W. O., Kuypers, D. R. J., Burra, P., Citterio, F., De Geest, S., Duvoux, C., Jardine, A. G., Kamar, N., Krämer, B. K., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001651 · Cited by 315
Post-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
Metadata
- Authors
- Hecking, M., Haidinger, M., Döller, D., Werzowa, J., Tura, A., Zhang, J., Tekoglu, H., Pleiner, J., Wrba, T., Rasoul-Rockenschaub, S., Mühlbacher, F., Schmaldienst, S., Druml, W., Hörl, W. H., Krebs, M., Wolzt, M., Pacini, G., Port, F. K., & Säemann, M. D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2012-04
- Volume
- 23
- Issue
- 4
- Pages
- 739-749
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2143724469
- Cited by
- 226
- References
- 10
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation. https://app.cochat.ai/papers/10.1681/asn.2011080835
- The paper
- Hecking, M., Haidinger, M., Döller, D., Werzowa, J., Tura, A., Zhang, J., Tekoglu, H., Pleiner, J., Wrba, T., Rasoul-Rockenschaub, S., Mühlbacher, F., Schmaldienst, S., Druml, W., Hörl, W. H., Krebs, M., Wolzt, M., Pacini, G., Port, F. K., & Säemann, M. D. (2012). Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2011080835
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.